San Francisco, January 17, 2026 — RISA Labs, an AI-driven healthtech startup developing an AI operating system for cancer care, has raised $11.1 million in a funding round co-led by Cencora Ventures and Optum Ventures.
The round also saw participation from Oncology Ventures, Z21 Ventures, and John Simon of Ventureforgood, along with existing investor Binny Bansal, the co-founder of Flipkart.
This latest round brings the company’s total funding to nearly $15 million, following its $3.5 million seed round in April 2025, which was also led by Binny Bansal and other early-stage investors.
Scaling AI for Smarter, Faster Cancer Care
The newly raised funds will be used to accelerate product development, expand partnerships with hospitals and oncology networks, and onboard new customers across the U.S. healthcare ecosystem, the company said in a statement.
“Our mission is to make cancer care faster, more coordinated, and data-driven,” said a spokesperson from RISA Labs. “We’re building the AI infrastructure that powers oncology workflows end-to-end — from diagnostics and treatment planning to patient coordination and administrative support.”
Building an AI Operating System for Oncology
Founded in the United States, RISA Labs is creating a comprehensive AI operating system for cancer care that automates both clinical and administrative workflows within oncology practices.
The platform is designed to integrate with existing healthcare systems, helping hospitals and clinics reduce manual effort, minimize administrative bottlenecks, and improve coordination between oncologists, labs, and insurers.
Key features of RISA Labs’ platform include:
-
Automated workflow management for diagnostics, treatment planning, and approvals
-
Predictive analytics to identify bottlenecks in care delivery
-
AI-powered documentation and communication tools for multidisciplinary teams
-
Data interoperability with EHR (Electronic Health Record) systems
By streamlining time-intensive tasks, the platform enables care teams to focus more on patient outcomes rather than administrative processes.
Addressing the Complexity of Cancer Care
Cancer treatment involves some of the most complex workflows in modern healthcare — from diagnostics and multidisciplinary care planning to ongoing patient management and regulatory documentation.
RISA Labs’ technology is aimed at simplifying and optimizing these processes using artificial intelligence and data automation, thereby improving the speed and accuracy of care delivery.
“Oncology practices face unique challenges where delays or miscommunication can directly affect patient outcomes,” said a partner from Optum Ventures. “RISA Labs’ AI platform helps eliminate inefficiencies, supporting care providers with smarter, data-driven tools that transform how cancer care is delivered.”
Investor Confidence in AI-Driven Healthcare
The participation of major healthcare and technology investors highlights growing confidence in AI’s role in transforming clinical operations.
-
Cencora Ventures and Optum Ventures — both leaders in healthcare innovation — bring deep expertise in scaling solutions for the medical and hospital ecosystem.
-
Oncology Ventures and Z21 Ventures contribute domain knowledge in cancer-focused innovations, further validating RISA Labs’ specialized positioning.
-
Binny Bansal’s continued investment underscores strong belief in the startup’s ability to build scalable, AI-powered infrastructure for healthcare.
“RISA Labs is reimagining cancer care delivery by building the digital operating layer the sector has been missing,” said a spokesperson from Cencora Ventures. “Their ability to bridge clinical precision with operational intelligence makes them a category-defining player in the emerging AI healthtech landscape.”
The Road Ahead: Expanding Across U.S. Cancer Networks
RISA Labs plans to expand its platform across large oncology providers and cancer care networks in the U.S., integrating with hospitals that manage high patient volumes and complex multidisciplinary workflows.
By deploying its AI operating system across the cancer care continuum, the company aims to:
-
Reduce turnaround times for diagnosis and treatment approvals
-
Enable better data coordination among oncologists, labs, and insurers
-
Increase patient throughput without compromising quality of care
-
Lay the foundation for global expansion, starting with North America
With the latest round of funding, RISA Labs is well-positioned to advance its goal of becoming the core AI infrastructure layer for oncology care worldwide.
About RISA Labs
RISA Labs is a U.S.-based AI healthtech startup building an AI operating system for cancer care. Founded by a team of engineers and healthcare professionals, the company uses artificial intelligence and automation to streamline clinical and administrative workflows in oncology.
Its platform helps healthcare providers improve coordination, reduce delays, and deliver more personalized, efficient care to patients.
RISA Labs is backed by investors including Cencora Ventures, Optum Ventures, Oncology Ventures, Z21 Ventures, Ventureforgood’s John Simon, and Flipkart co-founder Binny Bansal.
Key Highlights
-
Funding Raised: $11.1 million
-
Total Funding: $14.6 million to date
-
Lead Investors: Cencora Ventures, Optum Ventures
-
Other Investors: Oncology Ventures, Z21 Ventures, Ventureforgood, Binny Bansal
-
Founded: 2024 (U.S.)
-
Focus: AI-powered oncology workflow automation
-
Use of Funds: Product scaling, hospital integrations, U.S. market expansion
Ruchi Kumar is the associate editor at Entrepreneur News Network and TVW News India, where she leads editorial strategy, brand storytelling, and startup ecosystem coverage. With a strong focus on innovation, business, and marketing insights, he curates impactful narratives that spotlight India’s evolving entrepreneurial landscape.